Mercury Biopharmaceutical (ROCO:6932) Total Current Liabilities: NT$19.77 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6932 Mercury Biopharmaceutical Corp ROCO:6932
25 GF Score
Price NT$5.93
GF Value NT$36.00
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Mercury Biopharmaceutical Total Current Liabilities?

Mercury Biopharmaceutical ROCO:6932 -2.63% 25 Total Current Liabilities is NT$19.77 Mil as of Dec. 2025. GuruFocus rates ROCO:6932 with a GF Score™ of 25/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 1 warning sign investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Mercury Biopharmaceutical's total current liabilities for the quarter that ended in Dec. 2025 was NT$19.77

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Mercury Biopharmaceutical Total Current Liabilities Related Terms

Mercury Biopharmaceutical Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Mercury Biopharmaceutical's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mercury Biopharmaceutical Total Current Liabilities Chart

Mercury Biopharmaceutical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial 1.70 7.23 8.05 19.24 19.77

Mercury Biopharmaceutical Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.05 13.40 19.24 22.64 19.77
ROCO:6932
25GF Score
Mercury Biopharmaceutical Corp ROCO:6932
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mercury Biopharmaceutical Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Mercury Biopharmaceutical's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=10.695+2.843
+Other Current Liabilities+Current Deferred Liabilities
=6.232+0
=19.77

Mercury Biopharmaceutical's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=10.695+2.843
+Other Current Liabilities+Current Deferred Liabilities
=6.232+0
=19.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of NT$19.77 Mil mean?
Mercury Biopharmaceutical (ROCO:6932) has a Total Current Liabilities of NT$19.77 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Mercury Biopharmaceutical and its competitors.
Is Mercury Biopharmaceutical's Total Current Liabilities too high?
Mercury Biopharmaceutical's current Total Current Liabilities is NT$19.77 Mil. Overall, Mercury Biopharmaceutical has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Total Current Liabilities compare to ZTS and UTHR?
Mercury Biopharmaceutical's Total Current Liabilities of NT$19.77 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Mercury Biopharmaceutical and its competitors. Mercury Biopharmaceutical's current Total Current Liabilities is NT$19.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.93 — trading 83.5% below its estimated fair value. The current Total Current Liabilities is NT$19.77 Mil. Mercury Biopharmaceutical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Total Current Liabilities is NT$19.77 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?

Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued. The current stock price of NT$5.93 is trading 83.5% below its estimated GF Value™ of NT$36.00. GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:6932:

  • Total Current Liabilities: NT$19.77 Mil
  • GF Value™: NT$36.00 vs. price of NT$5.93 (83.5% below fair value)
  • GF Score™: 25/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mercury Biopharmaceutical Business Description

Address No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
25GF Score

Get the complete analysis for ROCO:6932

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$5.93
Price
NT$36.00
GF Value